Canadian specialist pharmaceutical company Aequus Pharmaceuticals has entered a broad research collaboration with the Centre for Drug Research and Development (CDRD).

The research collaboration will help establish pre-clinical safety and efficacy of select cannabinoid-based therapeutics that target neurological movement disorders, such as epilepsy, multiple sclerosis, Parkinson’s disease and Huntington’s disease.

CDRD president and chief executive officer Gordon McCauley said: “Our partnership with Aequus is a great example of the work we do with biotech across the country.

“There is a clear unmet medical need in the area of medical cannabinoid research and development where CDRD and Aequus can collaborate and share their respective expertise that could lead to new cannabinoid therapeutics and a pathway to clinical trials, particularly in neurological movement disorders.”

Headquartered in Vancouver, British Columbia, Canada, CDRD is the national drug development and commercialisation centre in the country.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

There is currently no sufficient data available to ensure proper therapeutic treatment protocols regarding the proper dosage and frequency for patients with a wide range of symptoms and disease areas.

"Our partnership with Aequus is a great example of the work we do with biotech across the country."

The collaboration will support preclinical studies, including in vitro and in vivo toxicology, pharmacology, and formulation optimisation in relevant disease models.

Following approvals from Health Canada, these preclinical studies will be conducted at CDRD’s facilities in Vancouver, British Columbia.

Products advanced through the new partnership will be commercialised by Aequus Pharmaceuticals.

The company aims to develop pharmaceutical grade products for patients seeking the use of optimised delivery versions of clinically validated formulations of medical cannabis.

Image: CDRD and Aequus collaborate and share their respective expertise to develop new cannabinoid-based therapeutics. Photo: courtesy of Business Wire.